S&P 500   3,957.63
DOW   33,852.53
QQQ   280.57
Three Reasons It’s Time To Get Bullish On Organigram
Forget tech, crypto, bonds, and treasuries – buy these instead  (Ad)
The AP Interview: IMF head urges China to end mass lockdowns
Survivor of Virginia Walmart mass shooting files $50M suit
The One Stock To Watch In This Market. (Ad)pixel
Can I Apply for Supplemental Security Income Online?
US stocks edge lower in unsteady trading, oil prices rise
The One Stock To Watch In This Market. (Ad)pixel
Why Investors Are Eating Up Restaurant Brands International
Opportunity Strikes! Hibbett, Inc Falls Flat On Strong Results
S&P 500   3,957.63
DOW   33,852.53
QQQ   280.57
Three Reasons It’s Time To Get Bullish On Organigram
Forget tech, crypto, bonds, and treasuries – buy these instead  (Ad)
The AP Interview: IMF head urges China to end mass lockdowns
Survivor of Virginia Walmart mass shooting files $50M suit
The One Stock To Watch In This Market. (Ad)pixel
Can I Apply for Supplemental Security Income Online?
US stocks edge lower in unsteady trading, oil prices rise
The One Stock To Watch In This Market. (Ad)pixel
Why Investors Are Eating Up Restaurant Brands International
Opportunity Strikes! Hibbett, Inc Falls Flat On Strong Results
S&P 500   3,957.63
DOW   33,852.53
QQQ   280.57
Three Reasons It’s Time To Get Bullish On Organigram
Forget tech, crypto, bonds, and treasuries – buy these instead  (Ad)
The AP Interview: IMF head urges China to end mass lockdowns
Survivor of Virginia Walmart mass shooting files $50M suit
The One Stock To Watch In This Market. (Ad)pixel
Can I Apply for Supplemental Security Income Online?
US stocks edge lower in unsteady trading, oil prices rise
The One Stock To Watch In This Market. (Ad)pixel
Why Investors Are Eating Up Restaurant Brands International
Opportunity Strikes! Hibbett, Inc Falls Flat On Strong Results
S&P 500   3,957.63
DOW   33,852.53
QQQ   280.57
Three Reasons It’s Time To Get Bullish On Organigram
Forget tech, crypto, bonds, and treasuries – buy these instead  (Ad)
The AP Interview: IMF head urges China to end mass lockdowns
Survivor of Virginia Walmart mass shooting files $50M suit
The One Stock To Watch In This Market. (Ad)pixel
Can I Apply for Supplemental Security Income Online?
US stocks edge lower in unsteady trading, oil prices rise
The One Stock To Watch In This Market. (Ad)pixel
Why Investors Are Eating Up Restaurant Brands International
Opportunity Strikes! Hibbett, Inc Falls Flat On Strong Results
NASDAQ:BCYC

Bicycle Therapeutics - BCYC Stock Forecast, Price & News

$27.61
+1.21 (+4.58%)
(As of 11/29/2022 12:00 AM ET)
Add
Compare
Today's Range
$26.05
$28.59
50-Day Range
$20.37
$29.01
52-Week Range
$12.08
$61.50
Volume
95,707 shs
Average Volume
345,269 shs
Market Capitalization
$819.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$52.40

Bicycle Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
89.8% Upside
$52.40 Price Target
Short Interest
Bearish
8.59% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.42mentions of Bicycle Therapeutics in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($3.82) to ($4.36) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.82 out of 5 stars

Medical Sector

545th out of 1,038 stocks

Pharmaceutical Preparations Industry

258th out of 510 stocks

BCYC stock logo

About Bicycle Therapeutics (NASDAQ:BCYC) Stock

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Receive BCYC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bicycle Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BCYC Stock News Headlines

Recap: Bicycle Therapeutics Q3 Earnings
See More Headlines
Receive BCYC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bicycle Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BCYC Company Calendar

Last Earnings
11/03/2021
Today
11/30/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/07/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BCYC
Fax
N/A
Employees
119
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$52.40
High Stock Price Forecast
$80.00
Low Stock Price Forecast
$30.00
Forecasted Upside/Downside
+89.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
12 Analysts

Profitability

Net Income
$-66,820,000.00
Net Margins
-669.65%
Pretax Margin
-681.96%

Debt

Sales & Book Value

Annual Sales
$11.70 million
Book Value
$11.78 per share

Miscellaneous

Free Float
27,017,000
Market Cap
$819.71 million
Optionable
Not Optionable
Beta
0.76

Key Executives

  • Dr. Kevin Lee M.B.A. (Age 53)
    Ph.D., CEO & Exec. Director
    Comp: $1.4M
  • Mr. Lee H. Kalowski M.B.A. (Age 41)
    MBA, Pres & CFO
    Comp: $832.36k
  • Sir Gregory Paul Winter CBE (Age 71)
    FMedsci, FRS, HonFRCP, HonFTSE, Co-Founder, Non-Exec. Director & Member of Scientific Advisory Board
    Comp: $40k
  • Dr. Michael Skynner B.sc. Ph.d. (Age 52)
    Ph.D., Chief Technology Officer
    Comp: $925.3k
  • Dr. Christian Heinis
    Scientific Founder
  • Mr. Alistair Milnes
    Chief Operating Officer
  • Dr. Nicholas Keen Ph.D. (Age 54)
    Chief Scientific Officer
  • Mr. David E. Borah CFA
    VP of Capital Markets & Investor Relations
  • Mr. Zafar Qadir
    Gen. Counsel
  • Dr. Gillian Langford
    Head of Clinical and Project Management













BCYC Stock - Frequently Asked Questions

Should I buy or sell Bicycle Therapeutics stock right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bicycle Therapeutics in the last year. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BCYC shares.
View BCYC analyst ratings
or view top-rated stocks.

What is Bicycle Therapeutics' stock price forecast for 2023?

12 brokerages have issued 12 month price objectives for Bicycle Therapeutics' stock. Their BCYC share price forecasts range from $30.00 to $80.00. On average, they anticipate the company's share price to reach $52.40 in the next year. This suggests a possible upside of 89.8% from the stock's current price.
View analysts price targets for BCYC
or view top-rated stocks among Wall Street analysts.

How have BCYC shares performed in 2022?

Bicycle Therapeutics' stock was trading at $60.87 at the beginning of the year. Since then, BCYC shares have decreased by 54.6% and is now trading at $27.61.
View the best growth stocks for 2022 here
.

Are investors shorting Bicycle Therapeutics?

Bicycle Therapeutics saw a drop in short interest in November. As of November 15th, there was short interest totaling 2,550,000 shares, a drop of 8.6% from the October 31st total of 2,790,000 shares. Based on an average daily volume of 218,700 shares, the short-interest ratio is currently 11.7 days.
View Bicycle Therapeutics' Short Interest
.

When is Bicycle Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our BCYC earnings forecast
.

How were Bicycle Therapeutics' earnings last quarter?

Bicycle Therapeutics plc (NASDAQ:BCYC) announced its quarterly earnings results on Wednesday, November, 3rd. The company reported ($0.59) earnings per share for the quarter, beating the consensus estimate of ($0.61) by $0.02. The company earned $4.33 million during the quarter, compared to the consensus estimate of $5.29 million. Bicycle Therapeutics had a negative trailing twelve-month return on equity of 31.56% and a negative net margin of 669.65%.

What other stocks do shareholders of Bicycle Therapeutics own?
When did Bicycle Therapeutics IPO?

(BCYC) raised $64 million in an initial public offering (IPO) on Thursday, May 23rd 2019. The company issued 4,300,000 shares at $14.00-$16.00 per share. Goldman Sachs, Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is Bicycle Therapeutics' stock symbol?

Bicycle Therapeutics trades on the NASDAQ under the ticker symbol "BCYC."

Who are Bicycle Therapeutics' major shareholders?

Bicycle Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Logos Global Management LP (6.74%), Samlyn Capital LLC (4.36%), Point72 Asset Management L.P. (4.23%), Tybourne Capital Management HK Ltd. (3.51%), First Light Asset Management LLC (2.37%) and Price T Rowe Associates Inc. MD (1.41%). Insiders that own company stock include Kate Bingham, Kevin Lee, Lee Kalowski, Nicholas Keen, Nigel Crockett, Pierre Legault, Plc Glaxosmithkline and Stephen B Alexander.
View institutional ownership trends
.

How do I buy shares of Bicycle Therapeutics?

Shares of BCYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bicycle Therapeutics' stock price today?

One share of BCYC stock can currently be purchased for approximately $27.61.

How much money does Bicycle Therapeutics make?

Bicycle Therapeutics (NASDAQ:BCYC) has a market capitalization of $819.71 million and generates $11.70 million in revenue each year. The company earns $-66,820,000.00 in net income (profit) each year or ($3.42) on an earnings per share basis.

How many employees does Bicycle Therapeutics have?

The company employs 119 workers across the globe.

How can I contact Bicycle Therapeutics?

Bicycle Therapeutics' mailing address is B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0, CB22 3AT. The official website for the company is www.bicycletherapeutics.com. The company can be reached via phone at 441223261503.

This page (NASDAQ:BCYC) was last updated on 11/30/2022 by MarketBeat.com Staff